GlassScriptPhysician profile
Thomas Elroy Dobyns
NPI 1336127323
$4,474.84
in general payments reported to CMS, 2019-2025
32 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $429 · 2021: $711 · 2022: $651 · 2023: $733 · 2024: $823 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,170 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,169.50 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $958.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $606.09 | 2021-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $353.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $348.07 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $324.54 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $268.22 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.05 | 2019-2025 | Jardiance |
| Amgen INC. | $164.44 | 2019-2025 | Otezla, Repatha, Evenity |
| Allergan, INC. | $134.45 | 2020 | |
| Pfizer INC. | $115.55 | 2019-2023 | |
| Astellas Pharma US INC | $111.79 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $95.76 | 2024-2025 | Rexulti, Nuedexta |
| Idorsia Pharmaceuticals US INC | $93.09 | 2023 | Quviviq |
| Exact Sciences Corporation | $92.97 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $90.85 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $69.36 | 2020-2021 | |
| Corium, LLC | $52.35 | 2023 | Adlarity |
| Teva Pharmaceuticals USA, INC. | $46.83 | 2022-2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $45.91 | 2019-2020 | |
| Dexcom, INC. | $44.12 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $36.85 | 2022 | |
| Abbott Laboratories | $34.77 | 2024-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $33.58 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.15 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $30.90 | 2023 | |
| Lundbeck LLC | $22.62 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $22.49 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.18 | 2024 | Xifaxan |
| Esperion Therapeutics, INC. | $14.74 | 2024 | Nexletol |
| Strongbridge US INC. | $12.88 | 2020 | |
| Sumitomo Pharma America, INC. | $11.74 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dobyns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.